TOPS System
Premia Spine, Ltd. · Decision date Oct 29, 2025
What did the FDA decide?
FDA records P220002/S010 as a supplement to PMA P220002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 29, 2025.
FDA approval order statement
introduction of a new plug sorting jig, adjustment to the plug cutting and insertion machine, and minor dimensional changes to the plug and top plate components to and improve sealing performance at the Premia Spine Ltd, Ramat Poleg, Netanya, Isreal and TAV Medical Ltd, Israel facilities
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Oct 29, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220002/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- Decision code
- OK30
- Decision date
- Oct 29, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, posterior spinal elements.
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220002 · Original PMA
TOPS System
P220002/S010 received
Application receipt date recorded by FDA.
P220002/S010 · FDA decision
30-Day Notice
P220002/S009 · Related supplement
TOPS System
P220002/S011 · Related supplement
TOPS System
Timeline entries are records held by MedtechLedger for P220002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TOPS SystemP220002 | Premia Spine, Ltd. | PMA approval | Jun 15, 2023 | FDA |
TOPS SystemP220002/S009 | Premia Spine, Ltd. | PMA supplement | May 29, 2026 | FDA |
TOPS SystemP220002/S011 | Premia Spine, Ltd. | PMA supplement | Sep 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Premia Spine, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7 Giborey Israel St., Ramat Poleg, Netanya, 4250407
Sources and methodology
- Original FDA record: P220002/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
